IL2 and hereditary clear cell renal cell carcinoma: In 1998, interleukin-2 (IL-2), a T-cell growth factor that aids in immune regulation and T-cell proliferation, became the second antitumor cytokine approved by the FDA when it was approved in the treatment of metastatic melanoma and renal cell carcinoma (Kirkwood et al., 2012).